Sep 2026· Ugeskrift for læger· Vol 188 37, pp. 1-8· 0 citations
Medicine
TL;DR
The Danish strategy for personalised medicine 2025-2027 includes initiatives for improving the use of pharmacogenetic information to guide drug therapy, and this review emphasises the need for improved infrastructure and data access for physicians.
Abstract
The Danish strategy for personalised medicine 2025-2027 includes initiatives for improving the use of pharmacogenetic (PGx) information to guide drug therapy. While PGx is already in use, its potential to prevent side effects and improve treatment success is not fully realised. 20% of Danish adults are already genotyped, which is a powerful resource, and this review emphasises the need for improved infrastructure and data access for physicians. The experience with return of genetic results is good but must be balanced with considerations on both cost-benefit and clinical effect.
Give the same dose of the same drug to two patients, and one may be cured while the other is harmed—a problem as old as prescribing itself. Much of that variability is written in the genome. Pharmacogenetics, the study of how inherited variation modifies drug response, has matured from a laboratory curiosity into a...
J. Sikarwar, Zunaira Amber, Nada Mohamme et al.· International Journal For Mu...· 0 citations
Specific laboratory practices that should be discontinued or established and followed as standard practice are proposed and ideal practices that would advance pharmacogenomics in clinical care are proposed.
E. Fieg, Benjamin Kerman, Lucas A. Berenbrok et al.· Clinical pharmacology and th...· 0 citations
Clozapine remains the most effective treatment for treatment-resistant schizophrenia, yet its use is constrained by concerns about safety and preventable adverse outcomes. Evidence on clozapine safety remains fragmented and methodologically heterogeneous, limiting translation into clinical practice. Pharmacovigilance,...
Pharmacogenomics (PGx) uses the variation in a patient’s genetic profile to assist with medication choice, with the goal of shortening the trial-and-error process of prescribing in psychiatry. Over the past few decades, PGx technology has evolved greatly to identify various genetic polymorphisms in drug-metabolizing en...
Rachael Cella, Helen Bian, Alexander Luo et al.· Pharmaceuticals· 0 citations
This work proposes a framework using genotype-stratified trials to characterize pharmacogenetic sources of variability, informing MIDD and MPID models while helping identify additional determinants of therapeutic response in CMC.
R. Gelineau-Morel, J. Leeder, Jonathan B. Wagner· Clinical pharmacology and th...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.